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O B J E C T I V E S The aim of our study was to evaluate the relationship between left ventricular (LV)
dyssynchrony and the risk of ventricular tachycardia (VT) or ventricular ﬁbrillation (VF) in patients
enrolled in the MADIT-CRT (Multicenter Automatic Deﬁbrillator Implantation Trial—Cardiac Resynchro-
nization Therapy) trial.
B A C KG ROUND Intraventricular mechanical dyssynchrony might be an important factor in ven-
tricular arrhythmogenesis by enhancing electrical heterogeneity in heart failure patients. The effects of
dyssynchrony have not yet been evaluated in a large cohort of implantable cardioverter-deﬁbrillator
(ICD) and cardiac resynchronization therapy with deﬁbrillator (CRT-D) patients.
METHOD S LV dyssynchrony was measured at baseline and at 12-months by speckle-tracking
echocardiography, deﬁned as the standard deviation of time to peak systolic strain in 12 LV myocardial
segments. The endpoint was the ﬁrst VT/VF/death or VT/VF. LV dyssynchrony was evaluated in 764 left
bundle branch block (LBBB) patients and in 312 non-LBBB patients.
R E S U L T S Baseline LV dyssynchrony was not predictive of VT/VF/death or VT/VF in LBBB or non-LBBB
patients in either treatment arm. In CRT-D patients with LBBB, improvement in LV dyssynchrony over a
year was associated with signiﬁcantly lower incidence of VT/VF/death (p  0.001) and VT/VF (p  0.001)
compared to ICD patients and to CRT-D patients with unchanged or worsening dyssynchrony. Among
LBBB patients, 15% decrease in LV dyssynchrony was associated with lower risk of VT/VF/death (hazard
ratio: 0.49, 95% conﬁdence interval: 0.24 to 0.99, p  0.049) and VT/VF (hazard ratio: 0.30, 95%
conﬁdence interval: 0.12 to 0.77, p  0.009) as compared to ICD patients. Patients without LBBB
receiving CRT-D did not show reduction in VT/VF/death or in VT/VF in relation to improving
dyssynchrony when evaluating cumulative event rates or risk of events.
CONC L U S I O N S Baseline LV dyssynchrony did not predict VT/VF/death or VT/VF in mild heart failure
patients with or without LBBB. CRT-induced improvement of LV dyssynchrony was associated with signiﬁcant
reduction of ventricular arrhythmias in patients with LBBB. (Multicenter Automatic Deﬁbrillator Implantation
Trial With Cardiac Resynchronization Therapy [MADIT-CRT]; NCT00180271) (J Am Coll Cardiol Img 2013;6:
432–44) © 2013 by the American College of Cardiology Foundation
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433ardiac resynchronization therapy (CRT)
has been shown to improve heart failure
symptoms, quality of life, and to reduce
heart failure hospitalizations in moderate
r severe heart failure patients (1–5). CRT corrects
he dyssynchronous left ventricular (LV) activation
attern, thereby increasing the LV systolic function,
nducing reverse remodeling and improving the
ong-term survival (6–8).
See page 445
The MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial–Cardiac Resyn-
chronization Therapy) study has recently demon-
strated that CRT combined with an implantable
cardioverter-defibrillator (CRT-D) reduces heart fail-
ure or death in mildly symptomatic or asymptomatic
heart failure patients with severe left ventricular dys-
function and a prolonged QRS (9). The MADIT-
CRT and the RAFT (Resynchronization-
Defibrillation for Ambulatory Heart Failure Trial)
studies showed that patients with left-bundle branch
block (LBBB) benefit the most from CRT compared
to non-LBBB patients, including patients with right-
bundle branch block (RBBB) and with intraventricu-
lar conduction delay (IVCD) (10,11).
Heart failure patients are at high risk of ventric-
ular tachyarrhythmias associated with worse out-
come (12). Furthermore, some studies indicated
proarrhythmic effects of CRT (13–15), whereas
others demonstrated antiarrhythmic effects, ex-
plained by improved hemodynamic status and left
ventricular reverse remodeling (16–19).
Intraventricular mechanical dyssynchrony might
play an important role in the development of
VT/VF by abnormal mechanical and subsequent
electrical activation inducing electrical heterogene-
ity. This association has not yet been investigated in
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verter defibrillator (ICD) and CRT-D patients.
The aim of the present study was to investigate
the association between LV dyssynchrony, CRT-
induced change in LV dyssynchrony, and the risk of
VT/VF/death or VT/VF events in patients with
LBBB and with non-LBBB, enrolled in the
MADIT-CRT study.
M E T H O D S
Patient population. The MADIT-CRT trial was a
prospective randomized multicenter trial designed
to determine whether CRT-D therapy
would reduce the primary endpoint of
heart failure events or death in mildly
symptomatic or asymptomatic heart fail-
ure patients (ischemic cardiomyopathy
with New York Heart Association func-
tional class I or II, nonischemic cardiomy-
opathy with New York Heart Association
functional class II) with severely depressed
left ventricular ejection fraction (LVEF)
30% and a wide QRS (130 ms). The
design, protocol (20), and results (9) of the
study had been published earlier. A total
of 1,820 patients were enrolled in 110
study centers in the United States, Can-
ada, and Europe. Patients were in sinus
rhythm and met the guideline criteria for
ICD therapy. Patients were randomly as-
signed to CRT-D or ICD alone in a 3:2
ratio. Screened patients were excluded
from enrollment, as specified earlier (20).
Echocardiographic methods. Echocardiog-
raphy investigators and sonographers from
each enrolling sites were qualified to per-
form echocardiography according to the
approved echocardiography protocol. Re-
cordings were analyzed off-line at the
Brigham and Women’s Hospital, Boston,
Massachusetts, as an independent echocardiogra-
phy core laboratory.
LV mechanical dyssynchrony was measured us-
ing B-mode speckle tracking software (Amid Car-
diac Performance Imaging, TomTec 1.0, Unter-
schleissheim, Germany), and analyzed off-line, as
reported previously (21). On the still 2-dimensional
images, the endocardium was traced in end systole
in the apical 4- and 2-chamber views. Segments
were manually adjusted if the tracking was subop-
timal. In case of at least 2 segments that could not
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434sis. Transverse strain is a measure of myocardial
thickening (like radial strain from parasternal view)
but the nomenclature is different as in this case the
apical view is utilized for data analysis (Fig. 1). In
this study, the strain curves were not smoothed,
although the software does a certain amount of
smoothing (by definition). The Tomtec software
computes the strain from the integration of the
strain-rate field; the strain-rate computation in-
volves the spatial derivative both of velocity and of
geometry slope (curvature) along the border. These
derivatives are computed with a filter (window
width) whose size is one-twelfth of the border
length (one-half of a segment). This is made to
avoid fluctuations more rapid than half the size of a
segment that are most likely due to errors than to
actual physiological behavior.
The measurements were evaluated by an investi-
gator blinded to randomization data, baseline clin-
ical characteristics, and outcomes. LV mechanical
dyssynchrony was defined as the standard deviation
of regional time-to-peak transverse strain, mea-
sured in the 12 segments of the left ventricle in the
apical 4- and 2-chamber views (septum, lateral,
anterior, and inferior walls; all of them subdivided
into basal, mid, and apical segments). The intra-
observer and interobserver variability for LV dys-
synchrony was 13.8% and 15.4% for time-to-peak
transverse strain, as reported elsewhere (21,22).
In all, 1,077 patients had digital echocardio-
grams of sufficient image quality to allow for 2-
dimensional speckle tracking analysis (21), after
excluding 607 patients with non-DICOM (Digital
Imaging and Communications in Medicine) images
and 136 patients with poor image quality. There-
fore, we analyzed 764 patients (42%) with LBBB
and 312 (17%) patients with non-LBBB at base-
line. One patient whose electrocardiogram
(ECG) pattern was unknown was excluded from
the analysis.
Paired echocardiograms from baseline and at 12
months eligible for dyssynchrony analysis were
available in 809 of 1,077 patients. The rest of the
patients had either poor image quality or their CRT
device was off at the time of the echocardiographic
analysis. Of the 809 patients with paired echocar-
diograms, 336 patients received ICD device, 473
patients received CRT-D. Patients with paired
echocardiograms had either LBBB ECG pattern
(n  572) or non-LBBB ECG pattern (n  237).
Device programming. Commercially available trans-
enous single or dual chamber ICD and CRT-D
evices (Boston Scientific) were implanted in thistudy, using standard techniques (20). Devices were
rogrammed with a recommendation of setting the
entricular tachycardia (VT) zone at 180 beats/min
nd ventricular fibrillation (VF) zone at 210 beats/
in. Sensitivity was programmed based on phy-
ician discretion. Detection was 2.5 s for the VT
one and 1.0 s for the VF zone. The pre-specified
tudy protocol recommended programming the
T zone therapy to burst-type antitachycardia
acing (ATP) with 8 pulses at 88% of the
easured cycle length with 10-ms decrement
etween bursts, and subsequent shock therapy,
ith the second suggestion of setting the shock at
efibrillation threshold plus at least 10 J. The
dditional shock therapies were suggested as
eing maximal energy shocks.
Patient follow-up, device interrogation. Patients had
a clinic follow-up 1 month after the device implan-
tation and then every 3 months until the end of the
trial or in case of heart failure or arrhythmic events.
Clinical evaluation and ICD interrogation was per-
formed at each follow-up visit. The ICD interro-
gation disks at follow-up and after ICD shocks
were sent to the interrogation core laboratory
(P.J.W., Stanford University) for categorization and
final evaluation of detected arrhythmias with ICD
therapy (ATP or shock).
Deﬁnitions and study endpoints. The relationship
between baseline LV dyssynchrony and study end-
points was analyzed in the total patient population
with LV dyssynchrony data regardless of treatment
assignment, split up by LBBB and non-LBBB
ECG pattern, because significant differences were
demonstrated in clinical outcome and ventricular
arrhythmia rate in these patient subgroups as re-
ported elsewhere (10). Patients were grouped into
quartiles of baseline LV dyssynchrony, as suggested
earlier (22).
The change in LV dyssynchrony was analyzed in
CRT-D and ICD patients. In this substudy, ICD
patients served as a control group, as it had already
been reported that ICD patients show less improve-
ment in LV dyssynchrony than CRT-D patients
(21). In this analysis, CRT-D patients with LBBB
and with non-LBBB were analyzed separately. The
change of LV dyssynchrony was calculated as the
difference in LV dyssynchrony from baseline to the
12-month recording. CRT-D patients were cate-
gorized into 3 groups based on the change: improv-
ing, unchanged, or worsening LV dyssynchrony.
Improving LV dyssynchrony was defined as a
15% decrease in LV dyssynchrony, and un-
changed dyssynchrony included dyssynchrony
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435Figure 1. Assessment of LV Dyssynchrony Before and After CRT-D Implantation
Two-dimensional speckle-tracking imaging from the apical 4-chamber view (A) before and (B) after cardiac resynchronization therapy with deﬁbrillator (CRT-D)
implantation. The curves represent transverse strain and left ventricular (LV) dyssynchrony measured by the standard deviation of time-to-peak transverse strain
in 12 LV segments. (A) Represents heterogeneous LV activation and signiﬁcant LV dyssynchrony before CRT-D implantation, whereas (B) shows synchronized LV
activation after CRT implantation in the same patient.
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436change 15% up to 15%. Worsening dyssyn-
chrony was defined as 15% positive change in LV
dyssynchrony.
Arrhythmia episodes were defined as any type of
therapy delivered including ATP and shocks. Def-
inition of VT was set to a rate from 180 beats/min
recommended programming) up to 250 beats/min,
entricular (V) rate  atrial (A) rate if 1:1 A:V, V-V
hanges drive AA changes. VF was defined as ven-
ricular rate 250 beats/min with disorganized ven-
ricular electrograms. Only appropriate therapy deliv-
red for VT or VF was considered in the present
nalysis. Arrhythmia episodes were adjudicated by an
ndependent adjudication committee blinded to treat-
ent assignment and clinical parameters.
The endpoint of the baseline analysis was the first
pisode of VT/VF or death and first VT/VF events.
hen analyzing the effects of LV dyssynchrony
hange at the 12-month follow-up, the first VT/VF
vents after 1 year assessment or death and first
T/VF after 1 year were considered as endpoints,
xcluding 25 patients with LBBB and 47 patients
ith non-LBBB who had VT/VF or death in the
rst year.
racteristics of Patients With LBBB and Baseline LV Dyssynchrony
Quartiles of Baseline LV Dyssyn
Less Dyssynchrony
117  23
(n  193)
167  10
(n  189)
208
(n 
65.4 11.1 63.1 11.6 62.8
45 (23) 62 (33) 60
35 (4.6) 45 (6.0) 49
24 (3.1) 34 (4.5) 40
16 (2.1) 12 (1.6) 12
ctional class II 96 (50) 103 (54) 118
97 (50) 86 (46) 77
54 (28) 40 (21) 36
ularization 45 (23) 51 (27) 30
71 (38) 59 (32) 57
24 (13) 14 (7) 17
mias 12 (6) 10 (5) 12
1.19 0.33 1.10 0.30 1.13
158.6 17.1 160.0 18.1 163.7
68.6 12.0 70.9 12.3 68.5
29.5 3.5 29.1 3.5 28.6
, ml/m2 119.1 24.2 124.5 29.6 129.0
, ml/m2 84.4 19.5 88.7 24.5 92.5
l/m2 46.2 9.7 45.1 10.5 47.3
100.1 116.7 107.3 142.2 118.6
n (%). Follow-up starts at enrollment.
peptide; BSA  body surface area; CABG  coronary artery bypass graft; LAV 
ic volume; LVEF  left ventricular ejection fraction; LVESV  left ventricular end
n; VT  ventricular tachycardia.Statistical analysis. Continuous variables are expressed
as mean  SD. Categorical data are summarized as
frequencies and percentages. Baseline clinical charac-
teristics were compared between the pre-specified
non-LBBB and LBBB subgroups, stratified by base-
line LV dyssynchrony quartiles or by changes over 1
year in LV dyssynchrony, using nonparametric Wil-
coxon or Kruskal-Wallis tests for continuous variables
and chi-square test or Fisher exact test for dichoto-
mous variables, as appropriate. When analyzing the
effects of LV dyssynchrony change, only the first
VT/VF events after the 12-month visit were consid-
ered as endpoints.
The correlation of baseline LV dyssynchrony and
baseline QRS duration was analyzed using Pearson
correlation method. Paired comparisons of baseline
LV dyssynchrony and change in LV dyssynchrony at
12 months in LBBB and non-LBBB patients were
analyzed using nonparametric Wilcoxon rank-sum test.
Cumulative probability of first VT/VF/death and
VT/VF episodes was determined according to the
Kaplan-Meier method, with comparisons of cumula-
tive event rates by the log-rank test in non-LBBB and
LBBB patients separate. Multivariate Cox propor-
Patients With Non-LBBB and Baseline LV Dyssynchrony
ny (ms) in LBBB Patients
More Dyssynchrony
Non-LBBB Patients
(n  312)
2
5)
274  41
(n  187) p Value
.8 64.6 11.2 0.064 65.0 10.6
) 65 (35) 0.079 36 (12)
) 47 (6.2) 0.970 88 (29)
) 39 (5.1) 0.659 74 (24)
) 13 (1.7) 0.356 22 (7)
) 106 (57) 0.191 52 (17)
) 81 (43) 0.191 260 (83)
) 34 (18) 0.071 140 (45)
) 37 (20) 0.040 141 (45)
) 62 (34) 0.387 221 (72)
13 (7) 0.220 40 (13)
11 (6) 0.976 25 (8)
31 1.18 0.35 0.031 1.24 0.47
.7 166.0 19.7 0.001 144.9 14.0
.7 65.3 9.2 0.001 66.0 10.8
3 22.1 5.7 0.037 30.1 3.3
.7 135.0 34.0 0.001 117.4 20.9
.2 97.2 28.3 0.001 82.3 16.4
6 48.2 11.7 0.017 45.2 10.4
8.2 138.8 181.4 0.141 161.2 198.7
trial volume; LBBB  left bundle branch block; LV  left ventricular; LVEDV 
lic volume; MI  myocardial infarction; NYHA  New York Heart Association;Table 1. Baseline Cha and
chro
 1
19
Age, yrs  10
Female (31
VT/VF/death (6.5
VT/VF (5.2
Death (1.6
Nonischemic NYHA fun (61
Ischemic (39
Prior CABG (18
Prior non-CABG revasc (15
Prior MI (30
Past atrial arrhythmias (9)
Past ventricular arrhyth (6)
Creatinine, mg/dl  0.
QRS, ms  18
Heart rate, beats/min  10
LVEF, %  3.
LVEDV indexed by BSA  27
LVESV indexed by BSA  22
LAV indexed by BSA, m  9.
BNP level, pg/ml  15
Values are mean  SD or
BNP  B-type natriuretic left a
left ventricular end-diastol -systo
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437tional hazards regression analysis was used to identify
and evaluate the impact of LV dyssynchrony on the
endpoint of first VT/VF or death and on VT/VF
events. The Cox model was adjusted for the variables
showing potential imbalances in clinical characteristics
in the pre-specified subgroups and for those predictive
of the endpoint. Interaction p values for LBBB and
non-LBBB are reported. Adjusted hazard ratios
(HRs) with their 95% confidence intervals (CIs) are
reported. All statistical tests were 2-sided; a p value of
0.05 was considered statistically significant.
R E S U L T S
Of the 1,077 patients with sufficient echocardio-
graphic images, in patients with non-LBBB (n 
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Figure 2. Cumulative Probability of VT/VF/Death and VT/VF Wit
Kaplan-Meier estimates of the cumulative probability of (A) ventricu
dle branch block (LBBB) patients, (B) VT/VF in non-LBBB patients, (C
quartiles of baseline dyssynchrony (Dys). The Kaplan-Meier graphs p
chrony quartiles and incidence of ventricular tachyarrhythmic event
were consistent in patients with LBBB and non-LBBB electrocardiog
cardiomyopathy (83%) compared to LBBB patients.312), 32 patients with ICD (27.1%), and 56 pa-
tients (28.9%) with CRT-D reached the endpoint
of VT/VF/death (p 0.74); in the LBBB subgroup
(n  764), 87 patients with ICD (29.3%) and 89
atients (19.1%) with CRT-D had VT/VF or death
p  0.001) from enrollment. During the mean
ollow-up of 2.3  0.9 years, 188 patients
17.7%) had VT, 55 (5.2%) had VF, and 75
atients died (7%), 22 of them (2%) after a VT or
F event. After the 12-month follow-up, 77 of
72 patients (13.4%) with LBBB had VT/VF/
eath, and 56 of them (9.8%) had VT or VF. In
atients with non-LBBB, 40 of 237 (16.8%)
atients had VT/VF or death, and 34 of them
14.3%) had VT or VF.
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438Baseline left ventricular dyssynchrony. Patients with
on-LBBB (n  312) and LBBB (n  764) ECG
pattern showed marked heterogeneity of LV dys-
synchrony before device implantation irrespective of
the QRS duration (r2  0.025, p  0.001). LBBB
patients exhibited more significant LV dyssyn-
chrony than non-LBBB patients (186.5  62.1 ms
vs. 167.5  74.5 ms, p  0.001).
The most relevant baseline clinical characteristics
in LBBB and non-LBBB patients are listed in
Table 1. LBBB patients with more pronounced LV
dyssynchrony had wider QRS complexes and worse
echocardiographic parameters, lower left ventricular
ejection fraction, and higher end-diastolic and end-
systolic volumes. Non-LBBB patients had wider
QRS-complexes and significantly lower heart rate
with increasing LV dyssynchrony. Many patients
Table 2. Baseline LV Dyssynchrony and the Risk of Ventricular
LBBB Electrocardiogram Pattern
Baseline LV
Endpoint VT/VF/Death
Non-LBBB (312 Patients/87
Hazard Ratio 95% CI
Baseline dyssynchrony Q2 1.25 0.74–2.13
Baseline dyssynchrony Q3 0.82 0.43–1.56
Baseline dyssynchrony Q4 0.73 0.40–1.35
Endpoint VT/VF
Non-LBBB (312 Patients/73
Hazard Ratio 95% CI
Baseline dyssynchrony Q2 1.04 0.57–1.90
Baseline dyssynchrony Q3 0.81 0.41–1.60
Baseline dyssynchrony Q4 0.76 0.40–1.45
*Q1 was used as reference group. †The model is adjusted for treatment, age a
left ventricular ejection fraction, previous revascularization, myocardial infarctio
CI  conﬁdence interval; other abbreviations as in Table 1.
Table 3. Baseline LV Dyssynchrony and the Risk of Ventricular
Stratiﬁed by Treatment Arm
Baseline LV
Endpoint VT/VF/Death
ICD (416 Patients/117 E
Hazard Ratio 95% CI
Baseline dyssynchrony Q2 1.18 0.68–2.05
Baseline dyssynchrony Q3 1.25 0.73–2.16
Baseline dyssynchrony Q4 0.95 0.55–1.75
Endpoint VT/VF
ICD (416 Patients/98 Ev
Hazard Ratio 95% CI
Baseline dyssynchrony Q2 0.92 0.50–1.72
Baseline dyssynchrony Q3 1.27 0.71–2.28
Baseline dyssynchrony Q4 0.97 0.52–1.80
*Q1 was used as reference group. †The model is adjusted for treatment, age a
left ventricular ejection fraction, previous revascularization, myocardial infarctio
CRT-D  cardiac resynchronization therapy with deﬁbrillator; ICD  implantable chad normal B-type natriuretic peptide values, re-
flecting the mildly symptomatic, asymptomatic
heart failure patient population. The extent of LV
dyssynchrony at baseline represented by quartiles
was not predictive of higher incidence of VT/VF/
death or VT/VF in non-LBBB or LBBB patients
(Fig. 2).
When assessing the risk of events, patients with
non-LBBB or LBBB ECG pattern did not show
increased risk of VT/VF or death and VT/VF
(Table 2) with increasing quartiles of baseline dys-
synchrony. Consistent with this, baseline dyssyn-
chrony was not predictive of subsequent VT/
VF/death or VT/VF in ICD or CRT-D patients
(Table 3).
CRT-D treatment did not modify the relation-
ship between LV dyssynchrony and VT/VF/death
ythmic Events in the Total Patient Population, Stratiﬁed by
ynchrony*†
ents) LBBB (764 Patients/172 Events)
p Value Hazard Ratio 95% CI p Value
0.41 1.06 0.67–1.67 0.81
0.54 0.93 0.59–1.45 0.75
0.32 1.00 0.63–1.60 0.98
ents) LBBB (764 Patients/136 Events)
p Value Hazard Ratio 95% CI p Value
0.90 1.21 0.70–2.06 0.50
0.54 1.12 0.67–1.89 0.67
0.41 1.24 0.72–2.13 0.43
ollment, ventricular arrhythmia episodes in the past, female sex, QRS duration,
the past, and left ventricular end-systolic volume index.
ythmic Events in the Total Patient Population,
ynchrony*†
ts) CRT-D (661 Patients/139 Events)
p Value Hazard Ratio 95% CI p Value
0.56 1.07 0.68–1.69 0.77
0.42 0.65 0.39–1.07 0.09
0.98 0.83 0.51–1.35 0.46
s) CRT-D (661 Patients/107 Events)
p Value Hazard Ratio 95% CI p Value
0.80 1.29 0.76–2.19 0.35
0.42 0.74 0.42–1.32 0.30
0.93 1.06 0.61–1.85 0.84
ollment, ventricular arrhythmia episodes in the past, female sex, QRS duration,
the past, and left ventricular end-systolic volume index.Arrh
Dyss
Ev
Ev
t enr
n inArrh
Dyss
ven
ent
t enr
n inardioverter-deﬁbrillator; other abbreviations as in Tables 1 and 2.
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439(p 0.27) or VT/VF (p 0.47) in the total patient
population.
Change in left ventricular dyssynchrony. At 12-
month follow-up, CRT-D patients with LBBB
(n  338) showed significant decrease in LV
dyssynchrony as compared to baseline (138.0 
63.3 ms vs. 189.4  63.4 ms, respectively, p 
.001). CRT-D patients with LBBB exhibited a
reater decrease of LV dyssynchrony as compared
o CRT-D patients with non-LBBB (n  135)
19.2 49.5 ms vs.2.1 56.4 ms, p 0.001).
ICD patients showed minimal changes in LV
yssynchrony as compared to patients with an
mplanted CRT-D (ICD 6.3  50.7 ms vs.
RT-D 14.3  52.1 ms; p  0.001). However,
7.5% (126 of 336 patients) of the ICD patients
xhibited a 15% improvement in LV dyssynchrony
s compared to 59% in the CRT-D group (281 of
73 patients, p  0.001). Furthermore, 111 of 336
atients (33%) in the ICD group worsened LV
yssynchrony compared to 96 of 473 patients (20%)
Table 4. Baseline Clinical Characteristics of ICD and CRT-D Patie
ICD
(n  336)
Age at enrollment, yrs 64.0 11.1
Female 83 (25)
Change in LV dyssynchrony at 1 yr 7 77
VT/VF/death after 1 yr 69 (267)
VT/VF after 1 yr 59 (277)
Death after 1 yr 16 (320)
Nonischemic NYHA functional class II 149 (44)
Ischemic 187 (56)
LBBB at baseline 234 (70)
RBBB at baseline 45 (13)
IVCD at baseline 57 (17)
Prior CABG 97 (29)
Non-CABG revascularization before enrollment 91 (27)
MI before enrollment 139 (42)
Atrial arrhythmias before enrollment 37 (11)
Ventricular arrhythmias before enrollment 23 (7)
Creatinine at baseline, mg/dl 1.17 0.32
QRS at baseline, ms 158.7 20.8
Heart rate at baseline, beats/min 68.0 11.3
LVEF at baseline, % 29.2 3.3
LVEDV indexed by BSA, ml/m2 126.2 29.7
LVESV indexed by BSA, ml/m2 89.8 24.1
LAV indexed by BSA, ml/m2 46.7 10.1
BNP level at baseline, pg/ml 116.8 133
Values are mean  SD or n (%).
IVCD  intraventricular conduction delay; RBBB  right bundle branch blockn the CRT-D group (p  0.001). iThe most relevant clinical characteristics of ICD
nd CRT-D patients, stratified by the change of
V dyssynchrony are listed in Table 4. Patients
ith improving LV dyssynchrony were more likely
o be female, younger, and have higher frequency of
onischemic etiology of heart failure as compared to
nchanged, or worsening dyssynchrony patients, or
o those with an implanted ICD. The B-type
atriuretic peptide level was significantly lower in
atients with improving LV dyssynchrony. The left
entricular end-diastolic and end-systolic volume
ercent change and left atrial volume percent
hange were greater in patients with improving LV
yssynchrony than in patients with no change or
orsening dyssynchrony or ICD patients, showing
vidence of more pronounced left ventricular re-
erse remodeling. There was no difference in drug
reatment among the patient subgroups. Patients
ith improving dyssynchrony had more often
BBB, and less often RBBB ECG pattern, than
atients with worsening dyssynchrony or with an
Stratiﬁed by Change in LV Dyssynchrony at 1 Year
CRT-D Patients
Dyssynchrony
Worsening
(n  96)
CRT-D Patients
Dyssynchrony
No Change
(n  96)
CRT-D Patie
Dyssynchro
>15% Impro
(n  281
66.9 10.3 64.5 11.5 63.8 11.
11 (11) 21 (22) 85 (30)
70 49 4 17 98 57
21 (75) 10 (86) 30 (251)
15 (81) 6 (90) 22 (259)
8 (88) 4 (92) 9 (272)
31 (32) 37 (39) 148 (53)
65 (68) 59 (61) 133 (47)
54 (56) 72 (75) 212 (75)
13 (14) 9 (9) 25 (9)
29 (30) 15 (16) 43 (15)
34 (35) 33 (34) 56 (20)
38 (40) 27 (28) 68 (24)
55 (58) 48 (50) 102 (37)
15 (16) 9 (10) 26 (9)
5 (5) 7 (8) 17 (6)
1.20 0.31 1.25 0.41 1.14 0.3
152.0 18.9 156.6 16.7 159.2 18.
66.2 10.5 69.4 10.4 66.7 10.
30.3 3.4 29.5 3.3 29.7 3.5
121.7 25.9 129.9 26.1 122.4 24.
85.4 21.1 92.0 21.0 86.5 20.
45.0 11.1 45.6 10.4 45.2 10.
179.9 202.0 135.3 148.7 147.0 213
 systolic blood pressure; other abbreviations as in Tables 1, 2, and 3.nts
nts
ny
ving
) p Value
1 0.077
0.003
0.001
0.001
0.001
0.223
0.002
0.002
0.003
0.273
0.008
0.004
0.038
0.002
0.365
0.897
2 0.099
3 0.004
7 0.102
0.033
4 0.024
3 0.017
2 0.072
.1 .2 0.049mplanted ICD.
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440In CRT-D patients with LBBB, a 15% decrease
n LV dyssynchrony was associated with significantly
ower incidence of VT/VF/death (p  0.001) and
T/VF (p  0.001) as compared to ICD patients or
o patients with CRT-D and unchanged, or CRT-D
nd worsening LV dyssynchrony (Figs. 3C and 3D).
owever, in CRT-D patients without LBBB, we
bserved no relationship between the changes in
V dyssynchrony and VT/VF/death or VT/VF
vents compared to the control group of ICD
mplanted patients (Figs. 3A and 3B).
Bundle branch block pattern significantly modified
he relationship between improving dyssynchrony and
he outcome of VT/VF or death (p  0.01), and
onsistent with these findings, significant interaction
as found between bundle branch pattern and dyssyn-
hrony with regard to VT/VF (p  0.009) (Table 5).
At 1 year, CRT-D patients with LBBB and a
Pr
o
ba
bi
lit
y 
of
 V
T/
VF
/D
ea
th
fo
r 
N
on
-L
B
B
B
 P
at
ie
nt
s
0.0
0.1
Years after 12 Month Echo
0.0 0.5 1.0
0.2
0.3
0.4
1.5
Dyss worse
Dyss no chg
Unadjusted P = 0.217
Patients at Risk
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Figure 3. Cumulative Probability of VT/VF/Death and VT/VF by
Kaplan-Meier estimates of the cumulative probability of (A) VT/V
(C) VT/VF/Death in LBBB patients, (D) VT/VF in LBBB patients. In
(Dyss) at 1-year was associated with less VT/VF/death and VT/VF
unchanged, or worsening LV dyssynchrony. In CRT-D patients wi
dyssynchrony and lower incidence of ventricular tachyarrhythmia
compared to LBBB patients. Abbreviations as in Figures 1 and 2.15% improvement in LV dyssynchrony showed cignificant, 51% risk reduction of VT/VF or death
ompared to ICD patients (HR: 0.49, 95% CI: 0.24
o 0.99, p  0.049) after adjustment for relevant
linical covariates (Table 5).
Consistent with these findings, CRT-D patients
ith LBBB and improving LV dyssynchrony had a
ignificant, 70% risk reduction in VT/VF events as
ompared to patients with an implanted ICD device
HR: 0.30, 95% CI: 0.12 to 0.77, p 0.01). CRT-D
atients with non-LBBB ECG pattern and a 15%
mprovement in LV dyssynchrony did not show de-
rease in the risk of VT/VF/death (HR: 1.12, 95% CI:
.48 to 2.58, p  0.80) or VT/VF events (HR: 1.05,
5% CI: 0.42 to 2.61, p  0.92) as compared to
atients with an implanted ICD (Table 5).
Importantly, worsening dyssynchrony was not
ssociated with an increased risk of VT/VF/death
r VT/VF in either bundle branch block pattern as
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 Dyss Worse   42 38 (0.05) 30 (0.05) 22 (0.12) 13 (0.23)
 Dyss No Chg   24 22 (0) 14 (0) 8 (0) 4 (0)
 Dyss chg>-15%   69 56 (0.08) 43 (0.11) 35 (0.14) 18 (0.20)
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 Dyss Worse   54 44 (0.04) 34 (0.10) 20 (0.19) 10 (0.19)
 Dyss No Chg   72 57 (0.07) 44 (0.09) 31 (0.09) 20 (0.09)
 Dyss chg>-15%   212 196 (0.01) 155 (0.03) 120 (0.03) 77 (0.05)
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nge in LV Dyssynchrony
ath in non-LBBB patients, (B) VT/VF in non-LBBB patients,
-D patients with LBBB, a 15% decrease in LV dyssynchrony
compared to ICD patients or to CRT-D patients with
on-LBBB, we did not ﬁnd an association between improved LV
atients with non-LBBB had mainly ischemic cardiomyopathyCha
F/de
CRT
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th n
s. Pompared to ICD patients (Table 5).
n
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441CRT-D patients with LBBB and no VT/VF
events exhibited a significant decrease in LV dys-
synchrony as compared to patients with LBBB and
VT/VF events, who did not decrease or even
increased the degree of LV dyssynchrony from
baseline (p  0.014). In CRT-D patients with
on-LBBB, the change in LV dyssynchrony was
ot associated with a decrease of VT/VF events
p  0.994) (Fig. 4).
D I S C U S S I O N
This study demonstrated that CRT-D patients
with LBBB and improving LV dyssynchrony at 1
year had significant risk reduction of the first
VT/VF/death and VT/VF as compared to ICD
patients. Worsening dyssynchrony in CRT-D pa-
tients was not associated with increased risk of the
first VT/VF/death or VT/VF as compared to ICD
patients. CRT-D patients with non-LBBB did not
show decrease in the first VT/VF/death or VT/VF
with improving LV dyssynchrony compared to
ICD patients. Baseline LV dyssynchrony was not
predictive of increased risk of first VT/VF/death or
VT/VF in asymptomatic or mildly symptomatic
heart failure patients in either treatment arm with
either bundle branch pattern.
Previous studies suggested that LV dyssynchrony
might be related to cardiac events in heart failure
patients (23). Cho et al. (24,25) demonstrated that
mechanical dyssynchrony was a powerful predictor of
mortality or cardiac events in heart failure patients
Table 5. Change in LV Dyssynchrony and Risk of Ventricular Ar
C
Endpoint VT/VF/Death
Parameter
No. of
Patients
Non-LB
(237 Patie
Hazard
Ratio 9
Dyssynchrony improving 15%:ICD 69:102 1.12 0.4
Dyssynchrony no change:ICD 24:102 NA
Dyssynchrony worsening:ICD 42:102 1.07 0.4
Endpoint VT/VF
Parameter
No. of
Patients
Non-LB
(237 Patie
Hazard
Ratio 9
Dyssynchrony improving 15%:ICD 69:102 1.05 0.4
Dyssynchrony no change:ICD 24:102 NA
Dyssynchrony worsening:ICD 42:102 0.90 0.3
*The model is adjusted for age at enrollment, previous ventricular arrhythmias,
duration, and left ventricular end-diastolic volume percent change.
NA  not applicable; other abbreviations as in Tables 1, 2, and 3.with normal and wide QRS. Penicka et al. (26),Fauchier et al. (27), and Bader et al. (28) reported that
LV dyssynchrony was prognostic of cardiac endpoints.
These studies analyzed heart failure patients without
implantable devices (ICD or CRT) and used either
radionuclide technique or pulsed-wave tissue Doppler
imaging to evaluate LV dyssynchrony.
However, several other studies demonstrated that
a greater degree of baseline LV dyssynchrony predicts
better outcome after CRT implantation (29–37). The
MIRACLE (Multicenter InSync Randomized
Clinical Evaluation) and the CARE-HF (Cardiac
Resynchronization–Heart Failure) trials showed
that interventricular mechanical delay was a pow-
erful prognostic factor of better outcome in both the
control and the treatment group (32).
Haguaa et al. (38) showed that mechanical dis-
persion assessed by strain echocardiography was an
independent predictor of arrhythmia events in a
smaller patient cohort after myocardial infarction.
LBBB patients were excluded from this analysis.
Another paper from this group showed similar
effects of dyssynchrony in nonischemic cardiomy-
opathy patients (39).
Our study is the first report to analyze VT/VF
events and LV dyssynchrony in mild heart failure
patients with LBBB and an implanted CRT-D
device and comparing them to patients with non-
LBBB. Although previous work has shown im-
provement in ventricular remodeling associated
with improvement in synchrony (21,22,40–42), we
also demonstrated that improved synchrony might
translate into reduction of ventricular arrhythmic
hmic Events in CRT-D LBBB and Non-LBBB Patients
e in LV Dyssynchrony*
Patients
/40 Events)
No. of
Patients
LBBB Patients
(572 Patients/77 Events)
CI p Value
Hazard
Ratio 95% CI p Va
.58 0.80 212:234 0.49 0.24–0.99 0.04
72:234 1.13 0.49–2.60 0.78
.52 0.88 54:234 1.80 0.83–3.90 0.14
Patients
/34 Events)
No. of
Patients
LBBB Patients
(572 Patients/56 Events)
CI p Value
Hazard
Ratio 95% CI p Va
.61 0.92 212:234 0.30 0.12–0.77 0.0
72:234 0.58 0.18–1.89 0.3
.32 0.83 54:234 0.95 0.35–2.60 0.9
entricular ejection fraction, female sex, myocardial infarction in the past, revascurhyt
hang
BB
nts
Interaction
p Value5% lue
8–2 9 0.01
NA
6–2 0.53
BB
nts
Interaction
p Value5% lue
2–2 1 0.009
7 NA
5–2 3 0.94
left v larization in the past, QRSevents in LBBB patients. The reduction of VT/VF
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442episodes in LBBB patients with improving LV dys-
synchrony might be explained by the more homoge-
nous left ventricular mechanical activation followed by
the electrical resynchronization itself (“mechanical to
electrical feedback”). Electrical resynchronization is
characterized by more uniform alterations in refracto-
riness, which might result in reduction of macro
re-entry arrhythmias (27). The reduction in LV dys-
synchrony might be correlated to the reduction in LV
volumes and favorable outcome as reported in this
patient cohort previously (21).
In the present study, LV dyssynchrony improve-
ment at 1 year, but not baseline LV dyssynchrony
was proven to be a strong predictor of ventricular
tachyarrhythmic events even after adjustment for
left ventricular end-diastolic volume change in the
multivariate Cox-model. We hypothesize that im-
provement in LV dyssynchrony and reverse remod-
eling are both surrogate markers of a favorable
Baseline Dyssynchrony
P = 0.52
186
188
LBBB Patients
12-Months Dyssynchrony
P = 0.01
155
125
M
ed
ia
n 
LV
 D
ys
sy
nc
hr
o
n
y 
(m
s)
100
120
140
160
180
200
VT/VF
No VT/VF
Baseline Dyssynchrony
P = 0.94
175
169
Non-LBBB Patients
12-Months Dyssynchrony
P = 0.91
157
151
M
ed
ia
n 
LV
 D
ys
sy
nc
hr
o
n
y 
(m
s)
100
120
140
160
180
200
VT/VF
No VT/VF
re 4. Change in LV Dyssynchrony in CRT-D Non-LBBB and
B Patients With Ventricular Arrhythmic Events or No Events
n CRT-D patients with non-LBBB, there was no difference in base-
or 12-month LV dyssynchrony whether patients had a ventricular
yarrhythmic event (green bars) or did not (pink bars). (B) In
D patients with LBBB and no ventricular arrhythmias, there was a
iﬁcant decrease in LV dyssynchrony, whereas in patients with ven-
lar tachyarrhythmias, no decrease in LV dyssynchrony was
rved. Abbreviations as in Figures 1 and 2.arrhythmic response to CRT.Patients with non-LBBB receiving CRT-D did
not appear to benefit from improvement in LV
dyssynchrony. One possible explanation for this lack
of benefit might be the significant overlap of non-
LBBB ECG pattern and patients with ischemic
etiology, in whom there may be a more heterogeneous
left ventricular activation and a greater degree of
ischemic scar which likely contributes to arrhythmo-
genesis. Although CRT is able to reduce LV dyssyn-
chrony and the heterogeneity of left ventricular acti-
vation, the arrhythmogenic potential represented by
the scar tissue might remain the same.
The strength of this analysis is ICD patients
serving as a control group and the change in LV
dyssynchrony at 1 year was categorized into 3
groups: improving, unchanged, or worsening LV
dyssynchrony. Importantly, patients with dyssyn-
chrony improvement showed significant risk reduc-
tion in ventricular arrhythmic events, whereas pa-
tients with worsening dyssynchrony did not show
an increased risk of ventricular arrhythmias.
A small proportion of ICD patients exhibited a
15% improvement in LV dyssynchrony, which might
be contributed to the improved medical treatment in
this patient group. These data are in alignment with
our previous study on LV dyssynchrony (21).
Study limitations. A possible limitation of our study is
the higher variation of LV dyssynchrony measure-
ments when compared to other established echocar-
diographic data (LVEF or LV volumes). The number
of patients in the unchanged and worsening LV
dyssynchrony subgroups was small, especially in the
non-LBBB patient group, which might be a limitation
of this analysis. There are limited numbers of speckles
to track in the transverse direction and the reproduc-
ibility of this method has therefore been questioned.
However, speckle tracking imaging has better repro-
ducibility than magnetic resonance imaging tagging or
other echo modalities to assess LV dyssynchrony (43).
In addition, we reported excellent reproducibility with
this technique in our echocardiography laboratory
(22). Another limitation of this analysis might be that
we only evaluated strain during systole; however,
maximum shortening might occur during diastole
(post-systolic shortening) in patients with LBBB.
C O N C L U S I O N S
Our study demonstrates that CRT-induced im-
provement in LV dyssynchrony in patients with
LBBB was associated with significant risk reduction
of first VT/VF/death and VT/VF as compared toA
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443atic heart failure patients with LBBB ECG pattern
undergoing CRT implantation, lack of improve-
ment in LV dyssynchrony with CRT might be
helpful to identify patients at higher risk of subse-12. Francis GS. Development of arrhyth-
mias in the patient with congestive
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